Opaleye Management as of Sept. 30, 2024
Portfolio Holdings for Opaleye Management
Opaleye Management holds 44 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Harrow Health (HROW) | 29.9 | $179M | 4.0M | 44.96 | |
| Tg Therapeutics (TGTX) | 8.9 | $53M | 2.3M | 23.39 | |
| Ocular Therapeutix (OCUL) | 7.3 | $44M | 5.0M | 8.70 | |
| Arvinas Ord (ARVN) | 5.2 | $31M | 1.3M | 24.63 | |
| Codexis (CDXS) | 4.5 | $27M | 8.8M | 3.08 | |
| Rhythm Pharmaceuticals (RYTM) | 4.4 | $26M | 500k | 52.39 | |
| Keros Therapeutics (KROS) | 3.8 | $23M | 395k | 58.07 | |
| Immunome (IMNM) | 3.0 | $18M | 1.2M | 14.62 | |
| Liquidia Corporation Com New (LQDA) | 2.8 | $17M | 1.7M | 10.00 | |
| Eton Pharmaceuticals (ETON) | 2.8 | $17M | 2.8M | 6.00 | |
| Edgewise Therapeutics (EWTX) | 2.3 | $14M | 523k | 26.69 | |
| Cargo Therapeutics (CRGX) | 2.0 | $12M | 541k | 21.86 | |
| Applied Therapeutics (APLT) | 1.9 | $11M | 1.3M | 8.50 | |
| Vaxcyte (PCVX) | 1.6 | $9.7M | 85k | 114.27 | |
| Nurix Therapeutics (NRIX) | 1.6 | $9.4M | 420k | 22.47 | |
| Acelyrin (SLRN) | 1.6 | $9.3M | 1.9M | 4.93 | |
| Trevi Therapeutics (TRVI) | 1.4 | $8.6M | 2.6M | 3.34 | |
| Biodesix (BDSX) | 1.2 | $7.0M | 3.8M | 1.83 | |
| Ginkgo Bioworks Holdings Class A New (DNA) | 1.1 | $6.7M | 820k | 8.15 | |
| Jasper Therapeutics Com New (JSPR) | 1.1 | $6.6M | 354k | 18.81 | |
| Xoma Corp Del Com New (XOMA) | 1.1 | $6.6M | 250k | 26.48 | |
| Nuvalent Inc-a (NUVL) | 1.1 | $6.5M | 64k | 102.30 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.9 | $5.6M | 335k | 16.60 | |
| Urogen Pharma (URGN) | 0.9 | $5.1M | 404k | 12.70 | |
| Protagonist Therapeutics (PTGX) | 0.8 | $4.7M | 105k | 45.00 | |
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.7 | $4.2M | 8.0M | 0.52 | |
| Cytokinetics Com New (CYTK) | 0.7 | $4.0M | 75k | 52.80 | |
| Karyopharm Therapeutics Note 3.000%10/1 (Principal) | 0.7 | $4.0M | 6.0M | 0.66 | |
| Gossamer Bio (GOSS) | 0.6 | $3.7M | 3.7M | 1.01 | |
| Zentalis Pharmaceuticals (ZNTL) | 0.6 | $3.6M | 967k | 3.68 | |
| Protara Therapeutics Com Stk (TARA) | 0.5 | $3.1M | 1.7M | 1.83 | |
| Rezolute Com New (RZLT) | 0.4 | $2.3M | 467k | 4.85 | |
| Catalyst Pharmaceutical Partners (CPRX) | 0.4 | $2.2M | 113k | 19.88 | |
| Abcellera Biologics (ABCL) | 0.3 | $2.1M | 800k | 2.60 | |
| Lyell Immunopharma (LYEL) | 0.3 | $1.9M | 1.4M | 1.38 | |
| Allakos (ALLK) | 0.3 | $1.6M | 2.4M | 0.65 | |
| Relmada Therapeutics (RLMD) | 0.3 | $1.6M | 480k | 3.24 | |
| Pepgen (PEPG) | 0.3 | $1.5M | 179k | 8.55 | |
| Revance Therapeutics (RVNC) | 0.2 | $1.4M | 275k | 5.19 | |
| Syros Pharmaceuticals Com New (SYRS) | 0.2 | $1.4M | 655k | 2.15 | |
| Aerovate Therapeutics (AVTE) | 0.2 | $920k | 440k | 2.09 | |
| Regulus Therapeutics (RGLS) | 0.1 | $840k | 535k | 1.57 | |
| Ibio Com New (IBIO) | 0.1 | $833k | 375k | 2.22 | |
| Adagio Med Hldgs (ADGM) | 0.0 | $285k | 111k | 2.58 |
